In fall of 2007, I believe FDA issued a non-approvable letter to MNTA based on their concern of not enough information provided with regard to immunogenicity.
Is it remotely possible that FDA is not fully onboard with Enoxaparin based on this concern and would still ask for verification of clinical safety ?
Market Data 
Markets 
AI
